Chamath Palihapitiya Reenters SPAC Market: Previous 18 Deals Show Average Loss of 14%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Source: Benzinga
New SPAC Launch: Chamath Palihapitiya has filed for a new SPAC, American Exceptionalism Acquisition Corp A (ticker AEAC), aiming to raise $250 million and invest in sectors like AI, clean energy, U.S. defense, or decentralized finance.
Investor Sentiment: Despite launching the new SPAC, investor sentiment remains cautious due to poor past returns from his previous SPAC deals, with a recent poll indicating that 70.7% of respondents were against him launching another SPAC.
Performance Overview: Palihapitiya has been involved in 18 SPACs, with an average return of -13.98%. His own SPACs have performed worse, averaging -26.24%, while PIPE deals he financed yielded a modest +1.34%.
Future Prospects: The new SPAC's structure includes milestone-based vesting for founder shares, which may encourage long-term investment. However, given past performance, interest from investors might be limited despite Palihapitiya's connections in Silicon Valley and the White House.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLOV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLOV
Wall Street analysts forecast CLOV stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.800
Low
3.00
Averages
3.35
High
3.70
Current: 4.800
Low
3.00
Averages
3.35
High
3.70
About CLOV
Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is a technology platform that empowers providers to deliver intuitive data-driven, personalized care to help physicians detect, identify, and manage diseases earlier. This physician-enablement platform is designed to synthesize comprehensive, longitudinal sets of data to generate provider-focused machine learning, artificial intelligence and rules-based insights, and to drive action by surfacing the relevant, personalized information about each patient to his or her provider. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jim Cramer's Insights on Multiple Stocks
- Fair Isaac Concerns: Despite growing worries about Fair Isaac's exposure to AI, analysts maintain a positive long-term outlook but choose to stay on the sidelines due to market uncertainties, reflecting caution regarding AI's impact on traditional business models.
- Clover Health Investment Strategy: Analysts acknowledge their overly conservative view on Clover Health, recognizing its speculative potential while favoring long-term holdings in United Health and CVS, indicating a preference for more stable companies.
- Vistra Price Volatility: Vistra's stock has experienced significant fluctuations, with analysts suggesting that the current price is too low and recommending a gradual build-up of positions, highlighting sensitivity to short-term market movements and expectations of a rebound.
- Stryker Consolidation Expectations: Analysts express disappointment that Stryker's anticipated consolidation has not materialized, indicating a failure of the market to deliver expected consolidation opportunities and reflecting a sense of disillusionment with industry consolidation trends.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Clover Health Plan Rating Upgrade Boosts Stock
- Rating Upgrade Impact: The U.S. District Court for the Southern District of Georgia ordered CMS to recalculate Clover's 2026 Star Rating, raising it from 3.5 to 4.5 stars, which will affect payment rates for 2027 and is expected to lead to higher bonus payments, thereby boosting revenue.
- Stock Price Surge: Shares of Clover Health Investments (CLOV) surged over 17% following the ruling, reaching their highest levels since November 2021, reflecting investor optimism about future revenue growth, especially given the company's claim of losing approximately $120 million in bonuses due to the rating reduction.
- Market Sentiment Shift: Retail sentiment surrounding CLOV on Stocktwits shifted from neutral to 'extremely bullish' amid high message volume, with investors widely believing that the ruling's impact could extend beyond the anticipated $120 million in revenue, with some predicting the stock could reach as high as $60 by 2027.
- Legal Context: Clover filed a lawsuit last November, claiming that CMS improperly implemented 20 quality measures that led to the downgrade of its PPO plan's Star Rating, and the court's ruling provides legal backing and market confidence for Clover's future growth.
See More
Clover Health and Chewy Show High Options Trading Volume
- Clover Health Options Volume: Clover Health Investments Corp (CLOV) has seen an options trading volume of 57,304 contracts today, representing approximately 5.7 million shares, which is 70.2% of its average daily trading volume of 8.2 million shares over the past month.
- High Call Option Activity: Within CLOV, the $4.50 strike call option has traded 14,324 contracts today, equating to about 1.4 million shares, indicating strong market expectations for the stock's future appreciation.
- Chewy Options Trading Dynamics: Chewy Inc (CHWY) has recorded an options trading volume of 61,142 contracts today, representing approximately 6.1 million shares, or 66.7% of its average daily trading volume of 9.2 million shares over the past month.
- Active Put Option: For CHWY, the $18 strike put option has seen 8,658 contracts traded today, amounting to approximately 865,800 shares, reflecting market concerns about potential declines in the stock's price.
See More
Conrad Wai Sells 220,426 Shares of Clover Health Stock
- Share Sale Details: Conrad Wai sold 220,426 shares of Clover Health stock at $3.99 per share, totaling approximately $879,000, demonstrating his strategic decision-making at a market peak.
- Ownership Structure: Post-sale, Wai retains 1,169,914 shares directly and 1,390,056 shares indirectly, indicating his confidence in the company's future and long-term investment intentions.
- Trading Plan Context: The transaction was executed under a Rule 10b5-1 trading plan established in March 2025, aimed at avoiding insider trading accusations, showcasing Wai's transparency and compliance.
- Market Performance Impact: On the day of the sale, Clover's stock hit a 52-week high of $4.23, reflecting the company's strong first-quarter performance with a 62% year-over-year revenue increase, highlighting its robust growth potential in the Medicare market.
See More
Clover Health CEO Sells 220,426 Shares Amid Strong Growth
- Transaction Overview: On May 28, 2026, Conrad Wai sold 220,426 shares of Clover Health stock in an indirect open-market transaction, generating approximately $879,000, which reflects his confidence in the company's future prospects.
- Ownership Structure Analysis: Post-transaction, Wai retains 2,559,970 shares of Class A Common Stock, with indirect holdings of 1,390,056 shares and direct holdings of 1,169,914 shares, indicating his continued commitment to maintaining control over the company.
- Market Context and Reaction: The shares were sold at $3.99 each, between the day's opening price of $3.64 and closing price of $4.18, reflecting a positive market response to the company's strong performance.
- Company Performance Highlights: Clover Health reported a 62% revenue increase in Q1, reaching $749.2 million, primarily driven by a 51% growth in Medicare Advantage membership, showcasing its robust position in the healthcare insurance market.
See More
Jim Cramer's Insights on Multiple Stocks
- Fair Isaac Concerns: Despite growing worries about Fair Isaac's exposure to AI, analysts maintain a positive long-term outlook but choose to stay on the sidelines due to market uncertainties, reflecting caution regarding AI's impact on traditional business models.
- Clover Health Investment Strategy: Analysts acknowledge their overly conservative view on Clover Health, recognizing its speculative potential while favoring long-term holdings in United Health and CVS, indicating a preference for more stable companies.
- Vistra Price Volatility: Vistra's stock has experienced significant fluctuations, with analysts suggesting that the current price is too low and recommending a gradual build-up of positions, highlighting sensitivity to short-term market movements and expectations of a rebound.
- Stryker Consolidation Expectations: Analysts express disappointment that Stryker's anticipated consolidation has not materialized, indicating a failure of the market to deliver expected consolidation opportunities and reflecting a sense of disillusionment with industry consolidation trends.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Clover Health Plan Rating Upgrade Boosts Stock
- Rating Upgrade Impact: The U.S. District Court for the Southern District of Georgia ordered CMS to recalculate Clover's 2026 Star Rating, raising it from 3.5 to 4.5 stars, which will affect payment rates for 2027 and is expected to lead to higher bonus payments, thereby boosting revenue.
- Stock Price Surge: Shares of Clover Health Investments (CLOV) surged over 17% following the ruling, reaching their highest levels since November 2021, reflecting investor optimism about future revenue growth, especially given the company's claim of losing approximately $120 million in bonuses due to the rating reduction.
- Market Sentiment Shift: Retail sentiment surrounding CLOV on Stocktwits shifted from neutral to 'extremely bullish' amid high message volume, with investors widely believing that the ruling's impact could extend beyond the anticipated $120 million in revenue, with some predicting the stock could reach as high as $60 by 2027.
- Legal Context: Clover filed a lawsuit last November, claiming that CMS improperly implemented 20 quality measures that led to the downgrade of its PPO plan's Star Rating, and the court's ruling provides legal backing and market confidence for Clover's future growth.
See More
Clover Health and Chewy Show High Options Trading Volume
- Clover Health Options Volume: Clover Health Investments Corp (CLOV) has seen an options trading volume of 57,304 contracts today, representing approximately 5.7 million shares, which is 70.2% of its average daily trading volume of 8.2 million shares over the past month.
- High Call Option Activity: Within CLOV, the $4.50 strike call option has traded 14,324 contracts today, equating to about 1.4 million shares, indicating strong market expectations for the stock's future appreciation.
- Chewy Options Trading Dynamics: Chewy Inc (CHWY) has recorded an options trading volume of 61,142 contracts today, representing approximately 6.1 million shares, or 66.7% of its average daily trading volume of 9.2 million shares over the past month.
- Active Put Option: For CHWY, the $18 strike put option has seen 8,658 contracts traded today, amounting to approximately 865,800 shares, reflecting market concerns about potential declines in the stock's price.
See More
Conrad Wai Sells 220,426 Shares of Clover Health Stock
- Share Sale Details: Conrad Wai sold 220,426 shares of Clover Health stock at $3.99 per share, totaling approximately $879,000, demonstrating his strategic decision-making at a market peak.
- Ownership Structure: Post-sale, Wai retains 1,169,914 shares directly and 1,390,056 shares indirectly, indicating his confidence in the company's future and long-term investment intentions.
- Trading Plan Context: The transaction was executed under a Rule 10b5-1 trading plan established in March 2025, aimed at avoiding insider trading accusations, showcasing Wai's transparency and compliance.
- Market Performance Impact: On the day of the sale, Clover's stock hit a 52-week high of $4.23, reflecting the company's strong first-quarter performance with a 62% year-over-year revenue increase, highlighting its robust growth potential in the Medicare market.
See More
Clover Health CEO Sells 220,426 Shares Amid Strong Growth
- Transaction Overview: On May 28, 2026, Conrad Wai sold 220,426 shares of Clover Health stock in an indirect open-market transaction, generating approximately $879,000, which reflects his confidence in the company's future prospects.
- Ownership Structure Analysis: Post-transaction, Wai retains 2,559,970 shares of Class A Common Stock, with indirect holdings of 1,390,056 shares and direct holdings of 1,169,914 shares, indicating his continued commitment to maintaining control over the company.
- Market Context and Reaction: The shares were sold at $3.99 each, between the day's opening price of $3.64 and closing price of $4.18, reflecting a positive market response to the company's strong performance.
- Company Performance Highlights: Clover Health reported a 62% revenue increase in Q1, reaching $749.2 million, primarily driven by a 51% growth in Medicare Advantage membership, showcasing its robust position in the healthcare insurance market.
See More
